![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, has secured a multi-million pound contract with a leading multi-billion dollar global ecommerce provider of reagents and tools to the research and clinical community.
As part of the agreement, Oxford Genetics will leverage its high throughput automated genomic engineering platform for CRISPR modification of mammalian cell lines.
Ryan Cawood, CEO, Oxford Genetics said, “This contract highlights Oxford Genetics’ commitment to providing the highest quality cell line engineering services to its global customer base and continuing to add value to their operations. We have moved away from manual processing, which is the norm in this market, in favour of automated, scalable platforms.
“This approach means we are well positioned to deliver the large number of custom-engineered cell lines per year that the global market is forecast to need.
“We are excited about this project which will see us significantly expand our product portfolio and continue to deliver innovative products and solutions to the pharmaceutical industry.”
Headquartered in Oxford, UK, Oxford Genetics is a leading synthetic biology company dedicated to developing and delivering technologies and services to its customers that will help to change the gene editing industry. The company’s use of automation allows it to develop new and innovative solutions, the latest of which is its mammalian CRISPR cell line engineering platform.
For more information about Oxford Genetics visit www.oxfordgenetics.com
About Oxford Genetics
Oxford Genetics, headquartered in Oxford, UK, is a leading synthetic biology company dedicated to creating technologies to streamline the discovery, development, and production of biologics, cell and gene therapies. This is enabled through cutting-edge bioinformatics that drive the rational design of complex biological systems at the DNA level which are then assembled on automated platforms using our DNA system, SnapFast. Examples include the development of optimised platforms for the discovery, engineering and production of antibodies, improved vectors, packaging and production cell lines for lentivirus and AAV manufacture, CRISPR libraries and CRISPR cell line engineering.
